Limits...
The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor.

Sun L, Sun X, Li Y, Xing L - Onco Targets Ther (2015)

Bottom Line: Malignant perivascular epithelioid cell tumor (malignant PEComa) is a rare disease for which the diagnostic criteria and treatment options have not been established.Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporter) function, increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake may indicate the over activation of mTOR pathway and may guide selectively inhibiting mTOR pathway treatment.The tumor had shown significant avidity on PET/CT as well as an evident response to sirolimus (rapamycin, Rapamune™) that supports the utility of mTOR inhibitors as an effective treatment for malignant PEComa.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.

ABSTRACT
Malignant perivascular epithelioid cell tumor (malignant PEComa) is a rare disease for which the diagnostic criteria and treatment options have not been established. Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporter) function, increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake may indicate the over activation of mTOR pathway and may guide selectively inhibiting mTOR pathway treatment. We report a malignant PEComa patient who presented for (18)F-FDG positron emission tomography/computed tomography (PET/CT) restaging. The tumor had shown significant avidity on PET/CT as well as an evident response to sirolimus (rapamycin, Rapamuneā„¢) that supports the utility of mTOR inhibitors as an effective treatment for malignant PEComa. Therefore, (18)F-FDG PET/CT is helpful in restaging and guiding treatment for malignant PEComa with mTOR inhibitors.

No MeSH data available.


Related in: MedlinePlus

The 18F-FDG PET/CT scans of the patient.Notes: (A and B) Axial CT image in the lung window and axial PET/CT fusion image at the level of inferior pulmonary vein. Circles: pulmonary metastases. (C and D) Axial CT image in the abdominal window and axial PET/CT fusion image at the level above hepatic portal. Arrows: liver metastases. (E and F) Axial CT image in the abdominal window and axial PET/CT fusion image at the level of hepatic portal. Boxes: metastatic foci growing from previous left kidney bed. (G) Maximum intensity projection image 18F-FDG PE T showed tumor emboli in bilateral upper pulmonary artery (arrowheads), left atrium (short arrow), and inferior vena cava (long arrow).Abbreviations: CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4525788&req=5

f2-ott-8-1967: The 18F-FDG PET/CT scans of the patient.Notes: (A and B) Axial CT image in the lung window and axial PET/CT fusion image at the level of inferior pulmonary vein. Circles: pulmonary metastases. (C and D) Axial CT image in the abdominal window and axial PET/CT fusion image at the level above hepatic portal. Arrows: liver metastases. (E and F) Axial CT image in the abdominal window and axial PET/CT fusion image at the level of hepatic portal. Boxes: metastatic foci growing from previous left kidney bed. (G) Maximum intensity projection image 18F-FDG PE T showed tumor emboli in bilateral upper pulmonary artery (arrowheads), left atrium (short arrow), and inferior vena cava (long arrow).Abbreviations: CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.

Mentions: 18F-FDG PET/CT scan was performed 1 month after pulmonary and kidney surgery to restage the disease. The PET/CT imaging showed bilateral multiple pulmonary metastases with maximum standardized uptake value (SUVmax) of 6.5 (circles in Figure 2A and B), liver metastases with SUVmax of 12.1 (arrows in Figure 2C and D), metastatic foci growing from previous left kidney bed with SUVmax of 7.3 (boxes in Figure 2E and F). In addition, whole body FDG PET showed multiple distant metastases, including the disseminating tumor emboli with intense FDG uptake (Figure 2G).


The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor.

Sun L, Sun X, Li Y, Xing L - Onco Targets Ther (2015)

The 18F-FDG PET/CT scans of the patient.Notes: (A and B) Axial CT image in the lung window and axial PET/CT fusion image at the level of inferior pulmonary vein. Circles: pulmonary metastases. (C and D) Axial CT image in the abdominal window and axial PET/CT fusion image at the level above hepatic portal. Arrows: liver metastases. (E and F) Axial CT image in the abdominal window and axial PET/CT fusion image at the level of hepatic portal. Boxes: metastatic foci growing from previous left kidney bed. (G) Maximum intensity projection image 18F-FDG PE T showed tumor emboli in bilateral upper pulmonary artery (arrowheads), left atrium (short arrow), and inferior vena cava (long arrow).Abbreviations: CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4525788&req=5

f2-ott-8-1967: The 18F-FDG PET/CT scans of the patient.Notes: (A and B) Axial CT image in the lung window and axial PET/CT fusion image at the level of inferior pulmonary vein. Circles: pulmonary metastases. (C and D) Axial CT image in the abdominal window and axial PET/CT fusion image at the level above hepatic portal. Arrows: liver metastases. (E and F) Axial CT image in the abdominal window and axial PET/CT fusion image at the level of hepatic portal. Boxes: metastatic foci growing from previous left kidney bed. (G) Maximum intensity projection image 18F-FDG PE T showed tumor emboli in bilateral upper pulmonary artery (arrowheads), left atrium (short arrow), and inferior vena cava (long arrow).Abbreviations: CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
Mentions: 18F-FDG PET/CT scan was performed 1 month after pulmonary and kidney surgery to restage the disease. The PET/CT imaging showed bilateral multiple pulmonary metastases with maximum standardized uptake value (SUVmax) of 6.5 (circles in Figure 2A and B), liver metastases with SUVmax of 12.1 (arrows in Figure 2C and D), metastatic foci growing from previous left kidney bed with SUVmax of 7.3 (boxes in Figure 2E and F). In addition, whole body FDG PET showed multiple distant metastases, including the disseminating tumor emboli with intense FDG uptake (Figure 2G).

Bottom Line: Malignant perivascular epithelioid cell tumor (malignant PEComa) is a rare disease for which the diagnostic criteria and treatment options have not been established.Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporter) function, increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake may indicate the over activation of mTOR pathway and may guide selectively inhibiting mTOR pathway treatment.The tumor had shown significant avidity on PET/CT as well as an evident response to sirolimus (rapamycin, Rapamune™) that supports the utility of mTOR inhibitors as an effective treatment for malignant PEComa.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.

ABSTRACT
Malignant perivascular epithelioid cell tumor (malignant PEComa) is a rare disease for which the diagnostic criteria and treatment options have not been established. Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporter) function, increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake may indicate the over activation of mTOR pathway and may guide selectively inhibiting mTOR pathway treatment. We report a malignant PEComa patient who presented for (18)F-FDG positron emission tomography/computed tomography (PET/CT) restaging. The tumor had shown significant avidity on PET/CT as well as an evident response to sirolimus (rapamycin, Rapamuneā„¢) that supports the utility of mTOR inhibitors as an effective treatment for malignant PEComa. Therefore, (18)F-FDG PET/CT is helpful in restaging and guiding treatment for malignant PEComa with mTOR inhibitors.

No MeSH data available.


Related in: MedlinePlus